Novartis Unveils Positive Study Data On Zolgensma Gene Therapy


(MENAFN- Swissinfo) Novartis has presented new study data on Zolgensma, its gene therapy treating spinal muscular atrophy (SMA). The data once again underscored the efficacy of this single-dose gene therapy in patients with SMA, according to a press release issued on Monday.

This content was published on March 4, 2024 - 13:16 2 minutes Keystone-SDA
  • العربية ar نوفارتيس السّويسريّة تكشف عن نتائج إيجابيّة لدراسة حول علاج زولجنسما الجّينيّ Read more: نوفارتيس السّويسريّة تكشف عن نتائج إيجابيّة لدراسة حول علاج زولجنسما الجّينيّ

The results of the SMART study added to what is known about the use of Zolgensma in patients who are older (1.5 – 9.1 years) and suffer more severely than the children treated in previous clinical trials.

In almost all cases, the motoric milestones of treated patients were maintained or even improved after 52 weeks. Many of these patients had switched therapies, having previously been treated with a different disease-modifying agent.

More More Swiss trade deal: Is India changing its tune on pharma patents?

This content was published on Feb 27, 2024 Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What's changed?

Read more: Swiss trade deal: Is India changing its tune on pharma patents?

The SMART study is reportedly the first open-label clinical trial of Zolgensma to include previously treated patients. Novartis announced that it will present the data at the Muscular Dystrophy Association (MDA) conference, which is taking place in the US until March 6.

Adapted from German by DeepL/dkk/amav

This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.

If you want to know more about how we work, have a look
here ,
and if you have feedback on this news story please write to
... .

External Content Your subscription could not be saved. Please try again. Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news

Get the most important news from Switzerland in your inbox.

Daily

Email

The SBC Privacy Policy provides additional information on how your data is processed.

I consent to the use of my data for the SWI swissinfo newsletter.

Articles in this story
  • Swiss trade deal: Is India changing its tune on pharma patents?

In compliance with the JTI standards

More: SWI swissinfo certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ... .

Read more More Swiss trade deal: Is India changing its tune on pharma patents?

This content was published on Feb 27, 2024 Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What's changed?

Read more: Swiss trade deal: Is India changing its tune on pharma patents?

MENAFN05032024000210011054ID1107935296


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.